Switchable CAR T-Cell System Shows Promise in Pancreatic Cancer Treatment

A novel cell-based immunotherapy using a switch control approach eradicated pancreatic cancer cells in mice, including cancer cells that had already spread to the liver and lungs, according to a new study.
 
Pancreatic cancer is an aggressive disease with one of the lowest survival rates of all cancers, indicating a critical unmet medical need for more effective therapies. The American Cancer Society estimates that 55,440 individuals will be diagnosed with pancreatic cancer in the United States in 2018 and 44,330 will die from the disease.
 
Immunotherapy with chimeric antigen receptor (CAR) T-cells have represented a novel strategy for targeting and destroying cancer cells; however, its efficacy treating solid tumors is inhibited by toxic adverse effects.
 
The study, published in Gut, used pancreatic cancer cells from patients with late-stage disease and transplanted them into mice. The researchers used a CAR T-cell therapy approach, taking patients’ immune cells and modifying them into CAR T-cells to specifically identify and eliminate the cancer cells. However, the researchers used a novel technology that allowed them to completely control the activity of the CAR T-cells.
 
The technology, called a switchable CAR T system, allows the treatment to be turned on and off, or have its activity changed to a desired level, which can minimize adverse effects and improve safety, according to the researchers.  
 
“Our work suggests that our new ‘switchable’ CAR T-cells could be administered to human patients with pancreatic cancer, and we could control their activity at a level that kills the tumor without toxic side effects to normal tissues,” lead author Dr Deepak Raj, from Queen Mary’s Barts Cancer Institute, said in a press release.
 
According to the study, switchable CAR T-cells followed by administration of the switch directed against human epidermal growth factor receptor 2 (HER2) induced complete remission in difficult-to-treat, patient-derived advanced pancreatic tumor models. Additionally, the switchable CAR T-cells were found to be as effective as conventional HER2 CAR T-cells.
 
The results indicate that a switchable CAR T system maintains the efficacy of treating metastatic pancreatic cancer while allowing for improved safety and reducing the risk of toxicity, the researchers concluded. 
 
References
 
Raj D, Yang M, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2018. http://dx.doi.org/10.1136/gutjnl-2018-316595
 
New immunotherapy offers potential cure for advanced pancreatic cancer [news release]. https://www.qmul.ac.uk/media/news/2018/smd/new-immunotherapy-offers-potential-cure-for-advanced-pancreatic-cancer.html. Accessed October 15, 2018.
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.
With oncology agents now flooding the specialty drug pipeline, it is important to keep up with the latest developments and look ahead at innovative therapies on the horizon.
Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$